STATINS AND NON CARDIAC ENDPOINTS

他汀类药物和非心脏终点

• 批准号: 2884452
• 负责人: BEATRICE A GOLOMB
• 金额: $ 72.26万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-08-20 至 2004-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2884452
• 关键词: HMG coA reductases; aggression; antihypercholesterolemic agent; behavioral /social science research tag; blood chemistry; clinical research; clinical trials; cognition; drug adverse effect; human subject; human therapy evaluation; hydropathy; oxidoreductase inhibitor; psychomotor function; serotonin; violence

DESCRIPTION (adapted from investigator's abstract): A relation of lowered cholesterol to increased aggressive behaviors (including suicide) and impaired cognition has been variably demonstrated and remains to be established or excluded with confidence. HMG-CoA reductase inhibitors ("statins") are the most widely used agents and their effects are of special interest. Purpose: To examine the effect of statins on aggressive responding, cognition, and serotonin in individuals with moderate LDL and no identified cardiovascular disease (CVD). Hypothesis: Statin therapy will increase aggressive responding on the PSAP (Point Subtraction Aggression paradigm, a standardized aggression measure that correlates with both violent behavior and serotonin); will reduce measures of cognition (including psychomotor speed and attention); and will change serotonin (gauged by whole blood serotonin), which may be a mediator of effects on behavior and perhaps cognition. Secondarily, it is hypothesized that simvastatin (lipophilic) will exert more potent effects on cognition (and perhaps aggression) than pravastatin (hydrophilic); that serotonin (5HT) changes will related to changes in aggressive responding and perhaps cognition; and that a "susceptible subset" may be defined by baseline characteristics including biochemistry, mood, personality, and extremes of cardiovascular reactivity.

描述（根据调查员的摘要改编）：降低的关系 胆固醇提高侵略性行为（包括自杀）并受损 认知已被广泛证明，尚待建立或 充满信心。 HMG-COA还原酶抑制剂（“汀类药物”）是最大的 广泛使用的代理及其影响特别感兴趣。目的：到 检查他汀类药物对积极反应，认知和 中度LDL且未鉴定的心血管的患者的5-羟色胺 疾病（CVD）。假设：他汀类药物疗法将增加积极反应 在PSAP上（点减法攻击范式，标准化的攻击 测量与暴力行为和5-羟色胺相关的）；会减少 认知度量（包括精神运动速度和注意力）；并将 改变5-羟色胺（由全血清素计量），这可能是 对行为甚至认知的影响。其次，假设 辛伐他汀（亲脂）将对认知（和 也许是侵略性）比pravastatin（亲水）；那5-羟色胺（5HT） 变化将与积极反应或认知的变化有关； 并且“易感子集”可以由基线特征定义 包括生物化学，情绪，个性和心血管极端 反应性。